Enzolytics(OTC) ENZC

Current Price$0.00

Market Cap$2.90M

Since IPO (2008)-100%

5 Year-100%

1 Year-14%

1 Month-45%

Enzolytics last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-07-24

Enzolytics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0%	USD 0.00	2026-07-17
1 month	-45.45%	USD 0.00	2026-06-24
3 month	+50%	USD 0.00	2026-04-24
Year to date	+100%	USD 0.00	2025-12-31
1 year	-14.29%	USD 0.00	2025-07-24
3 year	-98.7%	USD 0.05	2023-07-25
5 year	-99.69%	USD 0.19	2021-07-23
Since inception	-100%	USD 30,000.00	2008-12-29

Enzolytics Financials at a Glance

Market Cap

$2.90M

Revenue (TTM)

$0.00

Net Income (TTM)

-$404.09K

EPS (TTM)

-$0.00

P/E Ratio

-6.00

Dividend

$0.00

Beta (Volatility)

0.12 (Low)

Dividend

$0.00

Beta (Volatility)

0.12 (Low)

Price

$0.00

Volume

316,147

Open

$0.00

Price

$0.00

Volume

316,147

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

Dividend

$0.00

Beta (Volatility)

0.12 (Low)

Price

$0.00

Volume

316,147

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

ENZC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Enzolytics

Enzolytics Inc. is a biopharmaceutical company based in Plano, Texas, focused on developing and commercializing specialized protein-based therapies for severe infectious diseases. The company has patented anti-HIV treatments that have successfully completed clinical testing and has developed a unique methodology for manufacturing human IgG1 monoclonal antibodies.

Products and Services

Patented anti-HIV treatments with clinical testing success
Human IgG1 monoclonal antibodies for passive immunotherapy
Proprietary cell line engineered for effective HIV targeting

Growth Outlook

Potential market expansion in the biopharmaceutical sector
Innovative therapies addressing unmet medical needs
Strategic partnerships may enhance research and development capabilities

Financial Highlights

Recent quarterly net income of -$92,239 indicates ongoing investment in R&D
Trailing twelve months (TTM) revenue remains at $0, reflecting early-stage development
Cash and short-term investments total $200 million, providing operational flexibility

Enzolytics Inc. is positioned in the biotechnology industry, focusing on innovative solutions for infectious diseases. The company’s patented treatments and unique methodologies highlight its commitment to addressing significant health challenges. Despite recent financial losses, the substantial cash reserves indicate a strong foundation for future growth and development. The potential for market expansion and strategic partnerships may further enhance the company's prospects, making it an intriguing option for investors interested in the biopharmaceutical sector.

AI Generated • Jul 22, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Steven Sharabura

Website

www.enzolytics.com

Headquarters

Plano, TX 75074, US

ENZC Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

0.16%

Return on Capital

N/A

Return on Assets

-0.09%

Earnings Yield

-16.67%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.90M

Shares Outstanding

4.83B

Volume

316.15K

Avg. Volume

11.73M

Financials (TTM)

Gross Profit

-$22.09K

Operating Income

-$367.12K

EBITDA

-$345.04K

Operating Cash Flow

$114.66M

Capital Expenditure

$4.00

Free Cash Flow

$114.66M

Cash & ST Invst.

$200.00M

Total Debt

$996.34K

Enzolytics Performance Analysis

Enzolytics annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 0	N/A
2023	2023-12-31	USD 84,951	N/A
2024	2024-12-31	USD 0	N/A
2025	2025-12-31	USD 0	N/A

Enzolytics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	N/A
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	N/A

Enzolytics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -0.00	400.0%
2023	2023-12-31	USD -0.00	0.0%
2024	2024-12-31	USD -0.00	-90.0%
2025	2025-12-31	USD 0.00	N/A

Enzolytics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	N/A
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$5.52K

+0.0%

Gross Margin

0.00%

N/A

Market Cap

$2.90M

N/A

Market Cap/Employee

$2.90M

N/A

Employees

N/A

Net Income

-$92.24K

-4973.7%

EBITDA

-$77.46K

-451.0%

Quarterly Fundamentals

Name

Q2 2025YOY CHG

Total Cash

$200.00M

+0.0%

Total Debt

$996.34K

+0.0%

Accounts Receivable

$5.18K

+0.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$996.34K

+0.0%

Return on Assets

-0.09%

N/A

Return on Invested Capital

0.14%

N/A

Free Cash Flow

$114.84M

+28982.7%

Operating Cash Flow

$114.84M

+28982.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

VCNXVaccinex, Inc.

VCNXVaccinex, Inc.$1.18+0.00%

ISCOInternational Stem Cell Corporation

ISCOInternational Stem Cell Corporation$0.31+10.71%

BMNDFBiomind Labs Inc.

BMNDFBiomind Labs Inc.$0.05+0.00%

CNNACann American Corp.

CNNACann American Corp.$0.01-6.25%

NBCONeon Bloom, Inc.

NBCONeon Bloom, Inc.$0.01+0.00%

MDGEFMedigene AG

MDGEFMedigene AG$2.59+0.00%

CAIHFChia Tai Enterprises International Limited

CAIHFChia Tai Enterprises International Limited$0.28+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

ONDSOndas

ONDSOndas$7.80-0.02%

SOFISoFi Technologies

SOFISoFi Technologies$16.46-0.01%

FFord Motor Company

FFord Motor Company$14.37+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.48+0.07%

CLFCleveland-Cliffs

CLFCleveland-Cliffs$11.93+0.09%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$64.00-0.03%

STAKStak

STAKStak$9.27+6.02%

Questions About ENZC

What is the current price of Enzolytics?

Enzolytics is trading at $0.00 per share.

What is the 52-week range for Enzolytics?

Over the past 52 weeks, Enzolytics has traded between $0.00 and $0.00.

How much debt does Enzolytics have?

As of the most recent reporting period, Enzolytics reported total debt of $996.34K.

How much cash does Enzolytics have on hand?

Enzolytics reported $0.00 in cash and cash equivalents in its most recent financial results.

What is Enzolytics’s dividend yield?

Enzolytics does not currently have a dividend yield.

Enzolytics(OTC) ENZC

Enzolytics Financials at a Glance

ENZC News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Enzolytics

ENZC Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Enzolytics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ENZC

What is the current price of Enzolytics?

What is the 52-week range for Enzolytics?

How much debt does Enzolytics have?

How much cash does Enzolytics have on hand?

What is Enzolytics’s dividend yield?

Premium Investing Services